LBI-0996

THERAPEUTIC AREA

SOLID TUMOR CANCER

LBI-0996

Indications:
Taxane resistant metastatic & Advanced Breast Cancer
REGULATORY PATHWAY

505(b)(2) with improved formulation

TARGET INDICATION

First-in-class immediate release nanomedicine microtubule inhibitor effective against taxane resistant & p-glycoprotein drug resistant cancers

CURRENT DEVELOPMENT STATUS

Active pre-clinical development

NEXT DEVELOPMENT PHASE

IND enabling study

TIME TO HUMAN BENEFIT

Human trials beginning in 1.5 to 2 years

IMMEDIATE FUNDING REQUIRED?

Yes, please inquire